ANALYSIS: With an Obermatt 360° View of 20 (better than 20% compared with alternatives), overall professional sentiment and financial characteristics for the stock Panion & Bf Biotech are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Panion & Bf Biotech. The consolidated Value Rank has a low rank of 10 which means that the share price of Panion & Bf Biotech is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 90% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 37, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 37% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 45, which means that the company has a riskier financing structure than 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 28, which means that professional investors are more pessimistic about the stock than for 72% of alternative investment opportunities. ...read more